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Abstract
Background: Lymphangioleiomyomatosis (LAM) is a rare idiopathic disorder that occurs in women of childbearing
age, and consists of a diffuse proliferation of abnormal smooth muscle cells along the thoracic and abdominal
lymphogenous route.
Case presentation: We experienced a case of a 47-yo woman with recent history of systemic lupus erythematosus
(SLE) diagnosed with endometrial cancer, initially suspected to have metastasized to pelvic and para-aortic lymph
nodes based on preoperative diagnostic imaging. Subsequent pathological diagnosis revealed stage IB endometrial
cancer without evidence of lymph node involvement. Instead, enlarged pelvic and para-aortic lymph nodes were
found to be due to extrapulmonary LAM, from a primary lesion found inside the uterine myometrium. SLE
improved after surgery.
Conclusion: This is the first reported case of comorbid endometrial cancer, SLE, and aggressive LAM metastasizing
to regional lymph nodes, and strengthens the clinical evidence for a common role of mTOR pathway hyperactivity
and estrogen responsiveness in the pathophysiology of metastasizing lesions of the genital tract.
Background
Lymphangioleiomyomatosis (LAM), a rare disorder of
unknown incidence and prevalence, is characterized by
abnormal proliferation of smooth muscle cells in the
family of perivascular epithelioid cells (PEC) expressing
human melanin black (HMB)-45. Estimated to affect up
to 34 % of women with tuberous sclerosis complex
(TSC) [1], the lung is the most common site of involve-
ment, though extra-pulmonary LAM has been reported
in various other systems including gynecologic organs.
Although the precise cause of LAM remains unclear, its
etiology has recently been genetically linked to well-
characterized autosomal mutations of variable pene-
trance in TSC1 or TSC2 genes, as well as estrogen (E2)
responsiveness [2–4]. In the female genital tract, LAM
primarily affects the uterus [5–11], often mimicking
malignant diseases [12]. Despite several studies reporting
the usefulness of imaging for detection of lymph node
disease for suspected metastasis [13–15], imaging find-
ings in sporadic LAM without accompanying TSC are
difficult to interpret prior to systematic surgical staging,
leading to incorrect diagnoses in the absence of surgical
resections.
In this report, we describe the case of a woman
with SLE, found to have uterine LAM with lymph-
adenopathy, incidentally found on lymphoadenectomy
for treatment of advanced uterine endometrial cancer.
To the best of our knowledge, this is the first report
of LAM with SLE and endometrial cancer in a single
patient. This case report strengthens the possibility
that mTOR abnormalities may trigger a variety of
autoimmune and developmental disorders in women.
Case presentation
Case report
A 47-year-old Japanese woman, gravida 2, para 0, was
referred to our institution for abnormal uterine bleeding.
She had an extensive past medical history which
* Correspondence: nagasakak-tky@umin.ac.jp
1Department of Obstetrics and Gynecology, Faculty of Medicine, The
University of Tokyo, Tokyo, Japan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Suzuki et al. BMC Cancer  (2016) 16:390 
DOI 10.1186/s12885-016-2413-z
included SLE, anti-phospholipid antibody syndrome
(APS), idiopathic thrombocytopenic purpura (ITP), as
well as previous dissecting right vertebral artery
aneurysm and left cerebellar infarction. Her body mass
index (BMI) was 18.1. Workup revealed severe anemia
requiring an 8-unit red cell transfusion, and subsequent
to gynecological examination, endometrial sampling cy-
tology with conventional biopsy revealed Grade 1 endo-
metrioid adenocarcinoma; serum tumor markers were
obtained for evaluation and anticipated ongoing man-
agement of endometrial cancer; CA-125, CA19-9, and
CEA levels were 176 U/mL, 27U/mL, and 1.8 ng/mL, re-
spectively. Given her intravascular hypercoagulability
due to ITP, we administered continuous heparin along
with methylprednisolone (mPSL) pulse therapy to bring
her hematology profile within an acceptable range of tol-
erability for surgery. The patient’s laboratory results and
serologies are summarized in Table 1. Her medications
included prednisolone 20 mg twice a day, candesartan
8 mg daily, amlodipine 5 mg daily, rabeprazole sodium
3 g daily, and 600 μg subcutaneous teriparatide daily.
Magnetic resonance imaging (MRI) studies revealed
cancer invasion into the uterine myometrium (Fig. 1a).
On computed tomography (CT) imaging, abnormal
masses involving a large segment of multiple encapsu-
lated lymphadenopathies and measuring up to 6 cm
were present both in pelvic and para-aortic lymph nodes
(Fig. 1b), strongly suggesting retroperitoneal metastases
from endometrial cancer. However, positron emission
tomography-computed tomography (PET-CT) imaging
showed only slightly abnormal FDG uptake in the lymph
nodes (Standardized uptake value (SUV)-Max = 2.1)
(Fig. 1c) in comparison with high FDG uptake in the
uterus (SUV-Max = 19.1). Eventually, total hysterectomy
and bilateral salpingo-oophorectomy was performed for
primary staging, avoiding lymph node dissection due to
ongoing ITP-related thrombocytopenia.
On the basis of preoperative findings, we initially
diagnosed the patient as International Federation of
Gynecology and Obstetrics (FIGO) stage IIIC2 uterine
endometrial cancer, with 70 % myometrial invasion, lym-
phovascular invasion, and metastasis to the pelvic and
para-aortic lymph nodes. The patient subsequently
underwent adjuvant chemotherapy with paclitaxel
(175 mg/m2) and carboplatin (area under the curve, 6).
However, no change in size of lymphadenopathy was ob-
served after 3 cycles of chemotherapy. As her overall
condition improved, with platelets stabilizing at >80,000/
μL, and the patient wishing to avoid radiation therapy
due to the considerable complications, we then per-
formed dissection of retroperitoneal (pelvic and para-
aortic) lymph nodes. On gross exam, we found well-
circumscribed lymph node masses growing along the
lymph vessels (Fig. 2a), which were systematically dis-
sected (Fig. 2b), and found to have no metastatic in-
volvement or cured remnants of metastatic disease (0
out of 100 lymph nodes), although there was an option
to perform intraoperative diagnosis using frozen sections
if necessary. Final pathological diagnosis was consistent
with LAM arising from the retroperitoneal lymph nodes.
Microscopically, masses was composed of neoplastic
smooth muscle leiomyoma-like tumor cells with clear to
eosinophillic cytoplasm arranged in alveolar pattern
without necrosis (Fig. 3a), and slit-like vascular channels
lined by endothelial cells (Fig. 3b). Lymph node tumors
were focally positive for smooth muscle actin (SMA),
caldesmon, Melan A, HMB-45, and estrogen receptor
(ER), characteristics suggestive of LAM (Fig. 3c). Inter-
estingly, re-examination of uterine tissue from the pri-
mary operation revealed that regional LAM tissue was
co-localized with endometrial cancer with similarly ar-
ranged alveolar structure (Fig. 3d). Unlike normal myo-
metrium smooth muscle cells, immunostaining of
smooth muscle cells for HMB-45 and Melan A was posi-
tive in the LAM lesions. Moreover, we found that LAM
cells had locally invaded into the lymphatic vessels of
the myometrium. Taken together, our findings presented
herein suggest that LAM initially occurred in uterine
smooth muscle, subsequently invading the retroperiton-
eal lymph nodes by ascending via a lymphogenous route.
The patient is currently asymptomatic after the final
diagnoses of LAM and endometrial cancer (stage IB),
with no evidence of recurrence or metastasis to date. No
recurrent enlargement of lymph nodes or pulmonary
LAM has been observed on repeat CT imaging. How-
ever, she is currently maintained on low dose warfarin
therapy for SLE-related intravascular hypercoagulability.
Long-term follow-up by both internal medicine and
Table 1 Laboratory results and serologies at the first medical
examination
WBC 3.3×103/μL PT % 90.0 % RF 6 IU/mL
Hb 9.1 g/dL PT-INR 1.05 CH50 33.7 U/mL
Plt 2.2×104/μL APTT 62.0 s SS-A 240.0 U/mL
FDP 7.0 μg/mL C3 58 mg/dL
Alb 3.3 g/dL D-dimer 4.3 μg/mL C4 11 mg/dL
LDH 319U/L DS-DNA 0.9 IU/mL
BUN 24.1 mg/dL CEA 1.8 ng/mL SS-DNA 2.2 U/mL
Cre 0.85 mg/dL CA19-9 27 U/mL Antinuclear Ab +
Na 139 mEq/L CA125 176 U/mL Lupus AC 2.67
K 4.2 mEq/L CA15-3 12 U/mL Anti CL-IgG 79 U/mL
Cl 105 mEq/L NSE 11.0 ng/mL
AST 19 U/L SLX 25.0 U/mL ESR 48
ALT 23 U/L SCC 2.1 ng/mL
CRP 0.29 mg/dL CA72-4 4.4 U/mL
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gynecological healthcare providers will continue to be
important to correctly diagnose LAM and/or cancer-
related diseases.
Discussion
LAM is an idiopathic and intractable disease predomin-
antly affecting females of childbearing age. Classified into
pulmonary and extrapulmonary types, most patients are
identified by onset of pulmonary complications, such as
respiratory failure after pneumothorax [1]. Sporadic extra-
pulmonary LAM remains an unusual diagnosis in the
clinical setting [5]. No previous publication has reported
on its association with both SLE and endometrial cancer,
and this unique case suggests a possible common etiology
involving dysfunction of cell regulation functions of the
mTOR pathway.
As noted above, the loss of function mutations identi-
fied in TSC1 and TSC2, have been broadly detected in
pulmonary LAM cells, and likely explains the high cor-
relation found between pulmonary LAM and TSC [16].
These TSC1/TSC2 loss of function mutations activate
mammalian target of rapamycin (mTOR) protein
kinases, which promote both cell proliferation and
survival, have been implicated in various types of cancer
Fig. 1 a Axial preoperative T2-weighted contrast magnetic resonance imaging (MRI) shows endometrium thickness in the uterine body. It has
been diagnosed as Endometrial cancer of stage IB due to more than 50 % depth of myometrial invasion (red arrowhead). b The positron emission
tomographic (PET) with CT scan. c shows pathologically elevated glucose metabolism in enlarged paraaortic lymph nodes (orange arrowhead)
Fig. 2 a Intraoperative photo showing the swollen paraaortic lymph nodes left along the aortic vessels (red arrowhead). b The excised maximum
lymph node, approximately 7 cm in size, was solid and tender characteristic tumor
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[17]. Recently, the mTOR pathway has been found to
play a crucial role in the development of endometrial
cancer with high frequency of mutations in PTEN and/
or PIK3CA [18]; knowledge about genetic alterations in-
volved in this pathway offer potential treatment strat-
egies. Furthermore, constitutive activation of the mTOR
pathway has recently been reported in SLE [19]. Taken
together, the four diseases (LAM, TSC, SLE, and endo-
metrial cancer) appear to share a robust association with
mTOR pathway activation. It is noteworthy that no par-
ticular risk factors for endometrial cancer were found in
her personal or family history. Therefore, it is a reason-
able assumption that our patient’s history of SLE may be
causally related to both LAM and endometrial cancer.
Though we have not yet performed genetic testing for
germline mutations to reveal an association with mTOR
pathway deregulation that may cause TSC, the presence
of severe SLE, highly suggestive of constitutive hyperac-
tivation of mTOR signaling, may lead to endometrial
cancer as well as particularly aggressive LAM cells
present in uterine myometrium and lymphogenously in-
vading the retroperitoneal lymph nodes.
Conclusion
Clinicians should also be aware of a previous report sug-
gesting that extrapulmonary uterine LAM may precede
both TSC and pulmonary LAM by several years [4, 6], a
reasonable finding in the setting of ongoing and unre-
mitting mTOR hyperactivity and estrogen responsive-
ness. As such, we anticipate that this patient will
continue to be at risk for pulmonary LAM in the future.
In Japan, there have been several reported cases of pul-
monary LAM recurrence even after lung transplant. For
treatment of LAM, gonadotropin releasing hormone ag-
onists or progesterone therapy has been used for de-
cades, though their effectiveness remains controversial
and definitive treatment remains elusive. Recently, siroli-
mus, an mTOR inhibitor, has been investigated as a po-
tential therapeutic agent [20]. As a previous study has
described pulmonary LAM discovered a decade after ini-
tial diagnosis of a gynecologic lesion [5], novel therapies
may play a role in both treatment as well as prevention.
Based on currently available evidence, we feel that siroli-
mus on gynecologic field should be used with caution,
and considered only after thorough assessment and in
conjunction with scheduled imaging surveillance for re-
current disease.
As mentioned above, the gold standard for diagnosis
of LAM is made by histopathological findings. However,
as in this case, decision to pursue and timing of surgical
treatment is patient-specific. CT and MRI imaging re-
main the most accessible modalities for diagnosing
lymphadenopathy in the absence of surgical exploration.
Nonetheless, this case also highlights the appropriate
Fig. 3 a The maximum size lymph node was dissected from the
left lateral aortic lesion. Microscopically, masses was composed
of neoplastic smooth muscle leiomyoma-like tumor cells with
clear to eosinophillic cytoplasm arranged in alveolar pattern
without necrosis. b Slit-like vascular channels lined by endothelial
cells were seen in the lymph node. The cells with irregular
shaped nucleus were arranged in nested pattern. c Lymph node
tumors were focally positive for smooth muscle actin (SMA),
caldesmon, Melan A, HMB-45, and ER, characteristics suggestive
of LAM. Estrogen receptor (ER) was also focally positive. d Spindle cell
proliferation suggestive of regional LAM tissue was seen in the
re-examination of uterine tissue from the primary operation
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controversy that exists regarding the accuracy of identi-
fying lymph node metastasis from endometrial cancer
solely by integrated imaging techniques, which more re-
cently also include PET-CT imaging [15, 21]. In diseases
which may mimic metastasis associated with gynecologic
malignancy, we think PET-CT may offer substantial ad-
vantages in distinguishing key pathological feature of
lymphadenopathy. However, slightly increased FDG up-
take, as seen in this case, may cause difficulty in accurate
characterization of the underlying abnormality. A review
of more cases, further examining how to best evaluate
pelvic and para-aortic lymph node metastasis or LAM in
patients with comorbid endometrial cancer, is warranted
to clarify the optimal diagnostic modality for early detection
of sporadic LAM.
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